ALK and non-small cell lung carcinoma: This study aligns with established trends in NSCLC demographics, highlighting male predilection and the challenge of diagnosing advanced-stage disease. Patients harboring EGFR mutations were treated with tyrosine kinase inhibitors (TKIs), such as osimertinib or erlotinib, while those with ALK rearrangements received ALK inhibitors, such as alectinib.